Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 300.71M +58.4% |
| Revenue (ttm) | n/a |
| Net Income | -78.15M |
| EPS | -0.86 |
| Shares Out | 77.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 666,644 |
| Open | 3.920 |
| Previous Close | 3.890 |
| Day's Range | 3.820 - 4.000 |
| 52-Week Range | 1.350 - 4.600 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 8.20 (+110.8%) |
| Earnings Date | May 13, 2026 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $8.2, which is an increase of 110.80% from the latest price.
News
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program in ...
Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)
“In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including important data updates in kidney and islet cell transplantation and FDA Orphan Drug designation ...
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to t...
Eledon Pharmaceuticals Earnings release: Q1 2026
Eledon Pharmaceuticals released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Eledon Pharmaceuticals Quarterly report: Q1 2026
Eledon Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Eledon Pharmaceuticals files $500M mixed securities shelf
16:10 EDT Eledon Pharmaceuticals (ELDN) files $500M mixed securities shelf
Eledon Pharmaceuticals Registration statement: Registration filing
Eledon Pharmaceuticals filed a registration statement on May 1, 2026, providing details about a securities offering with the SEC.
Eledon Pharmaceuticals Proxy statement: Proxy filing
Eledon Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Eledon Pharmaceuticals Proxy statement: Proxy filing
Eledon Pharmaceuticals filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Eledon Pharmaceuticals Proxy statement: Proxy filing
Eledon Pharmaceuticals filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
NewcelX announces release of updated presentation on Type 1 Diabetes program
NewcelX (NCEL) announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (ELDN) and highlights the advancement of its f...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b l...
Eledon Pharmaceuticals Annual report: Q4 2025
Eledon Pharmaceuticals has published its Q4 2025 annual report on March 19, 2026.
Eledon Pharmaceuticals Earnings release: Q4 2025
Eledon Pharmaceuticals released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings
Pre-earnings options volume in Eledon Pharmaceuticals (ELDN) is normal with calls leading puts 724:1. Implied volatility suggests the market is anticipating a move near 11.7%, or 34c, after results ar...
Eledon announces updated data from islet transplant trial of tegoprubart
Eledon Pharmaceuticals (ELDN) announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D....
Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Tegoprubart showed non-inferior efficacy and a strong safety profile in kidney transplant studies, with promising results in islet cell transplantation and new Orphan Drug status for liver. Phase 3 planning is underway, targeting a large U.S. market, with a solid cash runway into next year.
Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart
Eledon Pharmaceuticals (ELDN) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug designation, ODD, to tegoprubart for the prevention of allograft rejection in liver tra...
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug desig...
NewcelX announces research agreement with Eledon Pharmaceuticals
NewcelX (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN). The collaboration is designed to advance combination strategies integrating NewcelX’s lead program, NCEL...
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company a...
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Phase II and Ib studies demonstrated strong safety and promising efficacy for a new transplant therapy, with regulatory discussions and a phase III trial launch expected by year-end. Expansion into islet cell and xenotransplant programs is underway, supported by a solid cash runway through 2027.
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D.
Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart
Eledon Pharmaceuticals (ELDN) announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplanta...